A 3D T1-weighted gradient-echo sequence for routine use in 3D radiosurgical treatment planning of brain metastases: first clinical results

1995 ◽  
Vol 5 (1) ◽  
pp. 19-25 ◽  
Author(s):  
H. Hawighorst ◽  
L. R. Schad ◽  
G. Gademann ◽  
S. Blüml ◽  
M. V. Knopp ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Treatment Planning ◽  
Clinical Results ◽  
Gradient Echo ◽  
Radiosurgical Treatment Planning

Radiosurgical treatment planning of brain metastases based on a fast, three-dimensional MR imaging technique

1994 ◽  
Vol 12 (5) ◽  
pp. 811-819 ◽  
Author(s):  
Lothar R. Schad ◽  
Stefan Blüml ◽  
Hans Hawighorst ◽  
Frederik Wenz ◽  
Walter J. Lorenz
Keyword(s):  
Mr Imaging ◽  
Brain Metastases ◽  
Treatment Planning ◽  
Imaging Technique ◽  
Three Dimensional ◽  
Radiosurgical Treatment Planning

Stereotactic external beam radiotherapy of brain metastases — Clinical results of a prospective study

1997 ◽  
Vol 33 ◽  
pp. S204
Author(s):  
A.L. Grosu ◽  
H.J. Feldmann ◽  
S. Stärk ◽  
M. Groß ◽  
P. Kneschaurek ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Prospective Study ◽  
External Beam Radiotherapy ◽  
Clinical Results ◽  
External Beam ◽  
A Prospective Study

“Donut’s Shape” Radiosurgical Treatment Planning for Large Cystic Metastatic Brain Tumors

2011 ◽  
Vol 54 (05/06) ◽  
pp. 286-289 ◽  
Author(s):  
M. Hayashi ◽  
M. Chernov ◽  
N. Tamura ◽  
M. Tamura ◽  
M. Izawa ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Treatment Planning ◽  
Metastatic Brain Tumors ◽  
Radiosurgical Treatment Planning

Identification of occult brain metastases amenable to stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment planning MRI: Results of a phase II trial of MGd and whole brain radiotherapy (WBRT) with stereotactic radiosurgery (SRS)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 2037-2037
Author(s):  
M. P. Mehta ◽  
A. Dagnault ◽  
P. Chabot ◽  
J. Suh ◽  
E. Chang ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Stereotactic Radiosurgery ◽  
Treatment Planning ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Whole Brain Radiotherapy ◽  
Gadolinium Contrast ◽  
Motexafin Gadolinium ◽  
Occult Lesion ◽  
Grade 3

2037 Background: Motexafin gadolinium (MGd) is a novel anti-cancer agent that selectively localizes in tumors and is detectable by MRI. Previous studies of patients (pts) with brain metastases (BM) demonstrated the detection of occult lesions after MGd administration not visible with gadolinium MRI contrast. The purpose of this study was to evaluate if MRI scanning after MGd improves SRS treatment-planning and treatment outcome by identifying and better defining lesions that can be treated with the SRS boost. Methods: Pts with 1–4 BM (< 4 cm diameter, or, if multiple, < 3cm) received WBRT (37.5 Gy) and MGd, 5 mg/kg/day during weeks 2–3 of WBRT, plus MGd, 5 mg/kg prior to treatment planning MRI and prior to SRS (21 Gy for lesions = 2 cm, 18 Gy for lesions 2.1–3.0 cm, and 15 Gy for lesions 3.1–4.0 cm). MRI was obtained within 4 weeks prior to enrollment with standard contrast, and after WBRT for SRS treatment planning with MGd and standard contrast. Patients were followed for neurologic progression and survival. Results: 45 patients with either lung cancer (76%), breast cancer (11%), melanoma (7%), or other cancers (7%), a median age of 58 years (range 42–74), and a median of 2 BM (range 1–4) were evaluable. In 9 of 42 patients (21%) with MRI data available, the MGd-based treatment planning MRI demonstrated at least one occult lesion not visualized on the screening MRI. The MGd-based treatment planning MRI detected 1 occult lesion in 6 pts, 2 occult lesions in 1 patient, and 3 occult lesions in 2 patients. Median survival for evaluable pts is 10 months; median time to neurologic progression or radiologic progresssion is not reached at 15 months. Grade 3+ neurotoxicity was limited to 1 pt with tumor necrosis and 1 pt with motor weakness. Most common Grade 3+ adverse events were pneumonia (9%) and DVT (9%). Conclusions: MGd-based treatment planning MRI for SRS identified occult BM that are amenable to SRS and are undetected with standard gadolinium contrast agents in 21% of the pts enrolled in this phase II trial. Treatment with MGd, WBRT and SRS to all lesions visualized resulted in improved survival and local control compared with historical results. [Table: see text]

Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 8052-8052
Author(s):  
R. H. Ansari ◽  
M. J. Edelman ◽  
C. P. Belani ◽  
M. A. Socinski ◽  
C. K. Obasaju ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Single Agent ◽  
The Elderly ◽  
Clinical Results ◽  
Phase Iii ◽  
Individual Treatment ◽  
Age Group ◽  
Standard Regimen ◽  
Platinum Based Chemotherapy

8052 Background: Approximately 50% of lung cancer patients (pts) are ≥ 70 y, however, this population has been historically underrepresented in clinical trials. Even among pts ≥ 70 y, doublet chemotherapy has been shown to be superior to single-agent therapy (Lilenbaum JCO 2005, Sederholm JCO, 2005), and the efficacy and safety of platinum-based chemotherapy doublets in NSCLC pts ≥ 70 years with good PS have been reported to be similar to those in younger pts (Fossella, ASCO 2003, #2528, Kelly, ASCO 2001, A-1313). The current analysis examined whether any differences were present by age in a three arm trial of GC or GP versus a standard regimen of PC. Methods: 1135 chemonaïve pts with stage IIIB or IV NSCLC were randomized to receive: G 1000 mg/m2 d 1,8 plus C AUC 5.5 d 1; or G 1000 mg/m2 d 1,8 plus P 200 mg/m2 d 1; or P 225 mg/m2 plus C AUC 6.0 d 1. Stratification was based on stage, baseline weight loss, and brain metastases. Cycles were repeated every 21 days up to 6 cycles or disease progression. Clinical results were retrospectively analyzed in by patient age. Results: See Table . Conclusions: In this trial of commonly used regimens for advanced NSCLC, pts 70–74 years of age had significantly longer survival than pts 75–79 years of age. Pts 80+ years of age also had lower survival than the 70–74 year age group, but this difference was not statistically significant. No pts 80+ years of age had brain metastases at study entry. There was no clear pattern with respect to the effectiveness of individual treatment regimens by age group. [Table: see text] [Table: see text]

scholarly journals Hair-sparing whole brain radiotherapy with volumetric arc therapy in patients treated for brain metastases: dosimetric and clinical results of a phase II trial

2014 ◽  
Vol 9 (1) ◽  
pp. 170 ◽  
Author(s):  
Annemieke De Puysseleyr ◽  
Joris Van De Velde ◽  
Bruno Speleers ◽  
Tom Vercauteren ◽  
Anneleen Goedgebeur ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Whole Brain Radiotherapy ◽  
Clinical Results ◽  
Whole Brain ◽  
Brain Radiotherapy ◽  
Volumetric Arc Therapy ◽  
Arc Therapy
Sign in / Sign up

Export Citation Format

Share Document